Spots Global Cancer Trial Database for mesotheliomas pleural
Every month we try and update this database with for mesotheliomas pleural cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma | NCT05278975 | Malignant Pleur... Malignant Pleur... Mesothelioma Mesotheliomas P... Mesothelioma; L... Pleural Effusio... | RSO-021 | 18 Years - | RS Oncology LLC | |
| A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma | NCT04214015 | Mesothelioma Mesothelioma Ma... Mesothelioma; L... Mesotheliomas P... Mesothelioma Pe... Mesothelioma; L... Mesothelioma; O... | No intervention | - | ProgenaBiome | |
| Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients | NCT04287829 | Mesotheliomas P... | Pembrolizumab Lenvatinib | 18 Years - | The Netherlands Cancer Institute | |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | NCT05451849 | Mesothelioma Mesotheliomas P... Mesothelioma, M... Mesothelioma Pe... Ovarian Cancer Ovarian Serous ... Pancreatic Canc... Pancreatic Aden... Colorectal Canc... Triple Negative... TNBC - Triple-N... Ovarian Adenoca... Pancreatic Neop... Colorectal Neop... Ovarian Neoplas... Cholangiocarcin... Non Small Cell ... | TC-510 Fludarabine Cyclophosphamid... | 18 Years - | TCR2 Therapeutics | |
| Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) | NCT04996017 | Mesotheliomas P... | Atezolizumab 12... Placebo | 18 Years - | Gruppo Oncologico Italiano di Ricerca Clinica | |
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | NCT03907852 | Mesothelioma Mesothelioma, M... Mesothelioma; P... Mesotheliomas P... Mesothelioma Pe... Cholangiocarcin... Cholangiocarcin... Ovarian Cancer Non Small Cell ... Non Small Cell ... High Grade Ovar... | gavo-cel fludarabine cyclophosphamid... Nivolumab Ipilimumab | 18 Years - | TCR2 Therapeutics | |
| The IMmunotherapy Pleural 5-ALA PDT | NCT04400539 | Mesotheliomas P... Malignant Pleur... | intrapleural ph... Nivolumab Injec... | 18 Years - | University Hospital, Lille | |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | NCT05451849 | Mesothelioma Mesotheliomas P... Mesothelioma, M... Mesothelioma Pe... Ovarian Cancer Ovarian Serous ... Pancreatic Canc... Pancreatic Aden... Colorectal Canc... Triple Negative... TNBC - Triple-N... Ovarian Adenoca... Pancreatic Neop... Colorectal Neop... Ovarian Neoplas... Cholangiocarcin... Non Small Cell ... | TC-510 Fludarabine Cyclophosphamid... | 18 Years - | TCR2 Therapeutics | |
| Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma | NCT04300244 | Cancer Cancer, Lung Cancer of Lung Mesothelioma Mesothelioma; L... Mesothelioma; P... Mesotheliomas P... | UV1 vaccine + l... ipilimumab nivolumab | 18 Years - | Oslo University Hospital | |
| CAR T Cells in Mesothelin Expressing Cancers | NCT03054298 | Lung Adenocarci... Ovarian Cancer Peritoneal Carc... Fallopian Tube ... Mesotheliomas P... Mesothelioma Pe... | huCART-meso cel... | 18 Years - | University of Pennsylvania | |
| Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM) | NCT03760575 | Mesotheliomas P... | Pembrolizumab Indocyanine Gre... Cisplatin Pemetrexed | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| The IMmunotherapy Pleural 5-ALA PDT | NCT04400539 | Mesotheliomas P... Malignant Pleur... | intrapleural ph... Nivolumab Injec... | 18 Years - | University Hospital, Lille | |
| Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma | NCT04300244 | Cancer Cancer, Lung Cancer of Lung Mesothelioma Mesothelioma; L... Mesothelioma; P... Mesotheliomas P... | UV1 vaccine + l... ipilimumab nivolumab | 18 Years - | Oslo University Hospital | |
| Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma | NCT05278975 | Malignant Pleur... Malignant Pleur... Mesothelioma Mesotheliomas P... Mesothelioma; L... Pleural Effusio... | RSO-021 | 18 Years - | RS Oncology LLC | |
| Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients | NCT04287829 | Mesotheliomas P... | Pembrolizumab Lenvatinib | 18 Years - | The Netherlands Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
